This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a fatty acid or fatty acid derived product, wherein the modified microorganism produces fatty acyl-CoA intermediates via a malonyl-CoA dependent but malonyl-ACP independent mechanism.

This document provides oilseed plants (e.g., pennycress plants) having increased levels of one or more saturated fatty acids, increased levels of one or more polyunsaturated fatty acids (PUFAs), altered (e.g., increased or decreased) levels of oleic acid, and/or altered (e.g., increased or decreased) levels of erucic acid. For example, oilseed plants having reduced polypeptide levels and/or reduced polypeptide activity of one or more polypeptides involved in triglyceride synthesis (e.g., diacylglycerol O-acyltransferase 1 (TAG1) can have increased levels of stearic acid, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid. Also provided herein are methods and materials for making and using oilseed plants having increased levels of one or more saturated fatty acids, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid.

In an aspect, the disclosure provides methods for making neurotransmitters in a host organism. The neurotransmitters can be cannabinoids and derivatives of cannabinoids. The host cells can be microalgae, fungi or other host cells. In a related aspect, the disclosure provides host cells engineered to have biochemical pathways for making neurotransmitters such as cannabinoids.

In an aspect, the disclosure provides methods for making neurotransmitters in a host organism. The neurotransmitters can be cannabinoids and derivatives of cannabinoids. The host cells can be microalgae, fungi or other host cells. In a related aspect, the disclosure provides host cells engineered to have biochemical pathways for making neurotransmitters such as cannabinoids.

The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.

The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a benzoxazinone-derivative herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising mutated PPO enzymes having a substitution at a position corresponding to position Arg128 of SEQ ID NO:2 and an amino acid substitution at a position corresponding to position Phe420 of SEQ ID NO:2, and methods of obtaining such plants.

The invention relates to recombinant microorganisms and methods of producing citronellal, citronellol, citronellic acid, and/or citronellal/citronellol pathway intermediates and precursors.

In an aspect, the disclosure provides methods for making neurotransmitters in a host organism. The neurotransmitters can be cannabinoids and derivatives of cannabinoids. The host cells can be microalgae, fungi or other host cells. In a related aspect, the disclosure provides host cells engineered to have biochemical pathways for making neurotransmitters such as cannabinoids.

Provided herein are engineered polypeptides that exhibit increased catalytic efficiency for unnatural cofactors and use of said polypeptides in engineered unnatural redox cofactor systems for whole-cell biomanufacturing and in cell-free applications.

This disclosure relates to mRNA therapy for the treatment of very long-chain specific acyl-CoA dehydrogenase deficiency (VLCADD). mRNAs for use in the invention, when administered in vivo, encode human very long-chain specific acyl-CoA dehydrogenase (VLCAD). mRNA therapies of the disclosure increase and/or restore deficient levels of VLCAD expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of acylcarnitine associated with deficient VLCAD activity in subjects.